2682-86-2

Basic information

• Product Name: Diethyl (3-pyridinylmethyl)phosphonate
• Synonyms: Diethyl (3-pyridinylmethyl)phosphonate
• CAS NO: 2682-86-2
• Molecular Formula: C₁₀H₁₆NO₃P
• Molecular Weight: 229.212701
• Mol File: 2682-86-2.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 97-101 °C(Press: 0.02 Torr)
• Appearance: /
• Density: 1.135±0.06 g/cm3(Predicted)
• PKA: 4.79±0.10(Predicted)
• CAS DataBase Reference: Diethyl (3-pyridinylmethyl)phosphonate(CAS DataBase Reference)
• NIST Chemistry Reference: Diethyl (3-pyridinylmethyl)phosphonate(2682-86-2)
• EPA Substance Registry System: Diethyl (3-pyridinylmethyl)phosphonate(2682-86-2)

Safety Data

• Hazardous Substances Data: 2682-86-2(Hazardous Substances Data)

Upstream product

• 3099-31-8 nicotinyl chloride 
• 2870-30-6 sodium diethyl phosphate 
• 762-04-9 phosphonic acid diethyl ester 

Downstream Products

• 1415818-78-8 C₁₉H₂₇N₂O₄P 
• 74095-34-4 (3-Pyridylmethyl)phosphonic Acid 
• 129078-91-7 <(1-benzylpyridino)-3-methyl>phosphonic acid 

Relevant articles and documents

Antimalarial and structural studies of pyridine-containing inhibitors of 1-deoxyxylulose-5-phosphate reductoisomerase

1-Deoxy-d-xylulose-5-phosphate reductoisomerase (DXR) in the nonmevalonate isoprene biosynthesis pathway is a target for developing antimalarial drugs. Fosmidomycin, a potent DXR inhibitor, showed safety as well as efficacy against Plasmodium falciparum malaria in clinical trials. On the basis of our previous quantitative structure-activity relationship (QSAR) and crystallographic studies, several novel pyridine-containing fosmidomycin derivatives were designed, synthesized, and found to be highly potent inhibitors of P. falciparum DXR (PfDXR) having Ki values of 1.9-13 nM, with the best one being ～11× more active than fosmidomycin. These compounds also potently block the proliferation of multidrug resistant P. falciparum with EC 50 values as low as 170 nM. A 2.3 A? crystal structure of PfDXR in complex with one of the inhibitors is reported, showing that the flexible loop of the protein undergoes conformational changes upon ligand binding and a hydrogen bond and favorable hydrophobic interactions between the pyridine group and the PfDXR account for the enhanced activity.

INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLMONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER

The present invention is directed to a compound is represented by Structural Formula (A):or a pharmaceutically acceptable salt therof. The present invention is also directed to a pharmaceutical composition comprising a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject having cancer, wherein the method comprises administering a therapeutically effective amount of a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof.

PHOTODEPHOSPHORYLATION OF PHOSPHONIC ACIDS

Photolysis of phosphonic acids in an alkaline aqeous solution gave 1-benzyl-methylpyridinium phosphates by the photocleavage of the C-P bond.